fbpx

Ovarian Cancer

Ovarian Carcinoma

Female, 64 years

Patient Internal ID 517462092

ICD-10 code

C56 Malignant Neoplasm of Ovary

Diagnosis (Incl. Metastases/Stage) and Year

March 2014
Ovarian Carcinoma pT2aN0M0 R0 G2 Stage II. In July 2019, disease recurrence and progression with Abdominal Metastasis was diagnosed (G3).

Previous Treatment

Surgery (Hysterectomy with Omentectomy), Chemotherapy (Carboplatin), Chemotherapy (Paclitaxel/Carboplatin), Chemotherapy (Carboplatin/Gemcitabine).

Prognosis and Survival Expectation

The average relative 5-year survival rate for those diagnosed with Distant Spread Ovarian Cancer is about 31%. The median survival of Metastatic Ovarian Cancer is 24.7 months (Swedish Cancer Registry).

Treatment Provided

Autologous DCV and CIK (12 doses) over a period of 18 months. Additionally, the patient received Umbilical Cord Blood Derived NK Cells (3 doses).

Patient Survival/Condition and Year
Date of Review: 17/02/2024

The patient has survived for over 8 years since the diagnosis and 3 years after the recurrence and progression of the disease. It can be concluded that the addition of Immunotherapy, alongside Surgery and Chemotherapy, has extended patient survival by an estimate of 13 months.

Disclaimer

We encourage you to learn more about your condition and treatment options to make informed decisions about your healthcare. However, please keep in mind that not all information available online or in other sources is accurate or relevant to your specific situation. It’s important to rely on credible, evidence-based sources such as official medical websites, peer-reviewed publications, or information provided by professional healthcare organizations. Always discuss any information you find with your healthcare provider before making decisions, as they can help clarify details, address concerns, and ensure the information is appropriate for your unique needs.